Ferring Pharmaceuticals announced that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately.

“Making the industry more patient-centric has always been a top priority for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health”

He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance. In addition, he will also be a member of the Ferring Executive Board.

Prior to this role, Prof. Dugi held various leadership roles at Boehringer Ingelheim, including Vice President Global Medical Affairs, Chief Medical Officer, and, most recently, Managing Director UK & Ireland.

“Making the industry more patient-centric has always been a top priority for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals.

A Professor of Medicine, with a specialty in Internal Medicine, Prof. Dugi continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.